Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDT
Company Participants
Josh Brodsky
Yvonne Greenstreet – CEO & Director
Jeffrey Poulton – CFO & Executive VP
Tolga Tanguler – Executive VP & Chief Commercial Officer
Pushkal Garg – Executive VP & Chief Research & Development Officer
Conference Call Participants
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Tommie Reerink – Goldman Sachs Group, Inc., Research Division
Tazeen Ahmad – BofA Securities, Research Division
Konstantinos Biliouris – Oppenheimer & Co. Inc., Research Division
Eliana Merle – Barclays Bank PLC, Research Division
Luca Issi – RBC Capital Markets, Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Whitney Ijem – Canaccord Genuity Corp., Research Division
Presentation
Operator
Thank you for standing by. My name is Sprilla, and I will be your conference operator today. At this time, I would like to welcome everyone to the Alnylam Pharmaceuticals Q2 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference over to the company. You may begin.
Josh Brodsky
Good morning. I’m Josh Brodsky, Vice President of Investor Relations at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Jeff Poulton, Chief Financial Officer; Tolga Tanguler, Chief Commercial Officer; and Pushkal Garg, Chief Research and Development Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.
During today’s call, as outlined on Slide 2, Yvonne will offer introductory remarks and provide some general context. Jeff will review our financials and guidance. Tolga will provide an update on our global commercial progress, and Pushkal will discuss our TTR franchise, our confidence in TRITON-CM and upcoming pipeline milestones before we open the call for your questions.
I would like to remind you
Credit: Source link
